| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/15/2003 | CN1098709C Exterior-applied medicine for treating trichomonas vaginitis and its preparing method |
| 01/15/2003 | CN1098684C Orally administerable pharmaceutical formulations |
| 01/15/2003 | CN1098681C Oil-in-water emulsion and its use and medicinal composition containing it |
| 01/15/2003 | CN1098679C Methods and compositions for pulmonary delivery of insulin |
| 01/14/2003 | US6506945 Process for preparing ether-capped poly(oxyalkylated) alcohol surfactants |
| 01/14/2003 | US6506928 Derivative in which fullerene is linked to at least one dendron having at least one protic group which imparts water solubility |
| 01/14/2003 | US6506906 Preparation and use of bifunctional molecules having DNA sequence binding specificity |
| 01/14/2003 | US6506885 Monoclonal antibodies to the drug tilmicosin and a method for detecting the same |
| 01/14/2003 | US6506881 Specific for human milk fat globule; complementarity determining region derived from variable domains of mouse monoclonal antibody |
| 01/14/2003 | US6506879 Endotoxin-free; genetically expressed in bacteria; atherosclerosis and cardiovascular disorder treatment |
| 01/14/2003 | US6506833 For use as stabilizers of emulsions and dispersions, and as slip agents in cosmetic and pharmaceutical solutions |
| 01/14/2003 | US6506803 Methods of preventing and treating microbial infections |
| 01/14/2003 | US6506730 Nasal transmucosal delivery of peptide conjugated with biocompatible polymers |
| 01/14/2003 | US6506420 Combinations of psyllium and chitosan for synergistic adsorption of triglyceride |
| 01/14/2003 | US6506419 Containing amino acid having a hydroxyl group or a dipeptide containing said amino acid; food, beverage; prevention of discoloration by oxidative polymerization |
| 01/14/2003 | US6506411 Anti-angiogenic compositions and methods of use |
| 01/14/2003 | US6506410 Sustained release microparticle and method for preparing the same |
| 01/14/2003 | US6506408 Implantable or insertable therapeutic agent delivery device |
| 01/14/2003 | US6506407 Drug coated with an organic acid-soluble polymer material and a saccharide,which rapidly generates an organic acid by the action enterobacteria |
| 01/14/2003 | US6506405 Methods and formulations of cremophor-free taxanes |
| 01/14/2003 | US6506399 Controlled release implantable drug delivery system composed of a plurality of botulinum toxin-incorporating polymeric microspheres. |
| 01/14/2003 | US6506381 Modified red blood cell that has surface molecules that neutralize chemical agents |
| 01/14/2003 | US6506365 Fibrin/fibrinogen binding conjugate |
| 01/14/2003 | US6506364 Administering such as sodium 3-iodo-4-hydroxybenzene sulfonate which is rapidly excreted without significant tissue uptake |
| 01/14/2003 | US6506363 Radioiodinated sulfonated phenols and process therefore |
| 01/14/2003 | CA2288760C Ascorbyl-phosphoryl-cholesterol |
| 01/14/2003 | CA2114629C Receptor conjugates for targeting antibiotics to bacteria |
| 01/14/2003 | CA2067975C Buffered matrix aspirin tablet |
| 01/14/2003 | CA2065270C Erection-inducing methods and compositions |
| 01/09/2003 | WO2003002598A2 Peptides for use as translocation factors |
| 01/09/2003 | WO2003002243A2 Method and device for electrochemical formation of therapeutic species in vivo |
| 01/09/2003 | WO2003002202A1 Antitumoral formulations of thioxanthenone |
| 01/09/2003 | WO2003002153A1 Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins |
| 01/09/2003 | WO2003002152A2 Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins |
| 01/09/2003 | WO2003002151A1 Oral pharmaceutical compositions with modified release of the active ingredient |
| 01/09/2003 | WO2003002150A1 Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma |
| 01/09/2003 | WO2003002149A2 Use of pigment such as e.g. titanium dioxide for obtaining a special optical effect on oral medicament or food |
| 01/09/2003 | WO2003002148A1 Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects |
| 01/09/2003 | WO2003002143A1 A novel engineered superantigen for human therapy |
| 01/09/2003 | WO2003002141A1 Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom |
| 01/09/2003 | WO2003002136A2 Stable formulation of modified glp-1 |
| 01/09/2003 | WO2003002133A2 Stabilisation of chlorophyll using medium chain triglyceride oils |
| 01/09/2003 | WO2003002123A2 Therapeutic combinations for the treatment of hormone deficiencies |
| 01/09/2003 | WO2003002102A1 Sustained release pharmaceutical composition |
| 01/09/2003 | WO2003002101A1 Oral pharmaceutical compositions with improved bioavailability |
| 01/09/2003 | WO2003002098A1 Tablet comprising cetirizine and pseudoephedrine |
| 01/09/2003 | WO2003002097A1 Process of thermodynamical activation of water-insoluble drugs loaded into cross-linked polymers |
| 01/09/2003 | WO2003002096A1 Methods and compositions for polyene antibiotics with reduced toxicity |
| 01/09/2003 | WO2003002093A1 Olopatadine formulations for topical administration |
| 01/09/2003 | WO2003002092A2 Controlled release composition comprising lactic acid polymer and hydroxynaphthoic acid, and method of producing the same |
| 01/09/2003 | WO2003002074A1 Emulsion compositions |
| 01/09/2003 | WO2003002069A2 Intradermal delivery of vaccines and gene therapeutic agents via microcannula |
| 01/09/2003 | WO2003002065A2 Hcv e1e2 vaccine compositions |
| 01/09/2003 | WO2003001876A2 T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds |
| 01/09/2003 | WO2002099026A8 Methods and formulations for enhancing the dissolution of a solid material in liquid |
| 01/09/2003 | WO2002080976A3 Hsa-free formulations of interferon-beta |
| 01/09/2003 | WO2002080901A3 Method for the production of anhydrous, pharmaceutical formulations of xanthogenates |
| 01/09/2003 | WO2002076376A3 A stable pharmaceutical composition of pravastatin |
| 01/09/2003 | WO2002069940A3 Highly flexible transdermal therapeutic system having nicotine as active substance |
| 01/09/2003 | WO2002064110A3 Carotenoid-loaded liposomes |
| 01/09/2003 | WO2002051443A3 Aqueous gel comprising a gelling agent such as kappa carrageenan and at least 85 % water |
| 01/09/2003 | WO2002049622A3 Transdermal system containing a novel high potency progestagen |
| 01/09/2003 | WO2002043756A3 Method for obtaining antigenic aggregates and the use thereof in formulations |
| 01/09/2003 | WO2002038127A3 Particle formation methods and their products |
| 01/09/2003 | WO2002036097A3 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 01/09/2003 | WO2002036067A3 Long-acting cytokine derivatives and pharmaceutical compositions comprising them |
| 01/09/2003 | WO2002034236A3 Lipid formulations for target delivery |
| 01/09/2003 | WO2002031142A3 Antisense nucleic acid against alphav integrin |
| 01/09/2003 | WO2002020558A3 Method for binding, in solution, a peptide and a lipophilic vector and uses thereof |
| 01/09/2003 | WO2002009716A3 Use of an aldehyde 5-oxo-1,2,4-triazine hydrazide for the treatment of cancer |
| 01/09/2003 | WO2001098294A3 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 01/09/2003 | WO2001079480A9 Albumin fusion proteins |
| 01/09/2003 | WO2001062297A9 Compositions and methods for enhancing drug delivery across biological membranes and tissues |
| 01/09/2003 | US20030009145 Delivery of drugs from sustained release devices implanted in myocardial tissue or in the pericardial space |
| 01/09/2003 | US20030009004 For use in solubilization of insoluble drug and a delivery system of proteins, genes or drugs |
| 01/09/2003 | US20030008971 Hydrogel entrapping therapeutic agent and stent with coating comprising this |
| 01/09/2003 | US20030008904 For therapy of angina pectoris, atherosclerosis, hypertension and hyperlipidemia |
| 01/09/2003 | US20030008902 Paroxetine tablets & capsules |
| 01/09/2003 | US20030008865 Xanthine-and phenazone-acesulfame-H complexes having improved taste, process for their preparation and their use |
| 01/09/2003 | US20030008862 Function as sulfatase and/or blocking estrogen receptors; prophylaxis and therapy |
| 01/09/2003 | US20030008843 Bulking agents as satiety agents |
| 01/09/2003 | US20030008840 Methods for treating cancer |
| 01/09/2003 | US20030008835 Bioavailability of drug substance, are convenient to administer, and are stable |
| 01/09/2003 | US20030008827 Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| 01/09/2003 | US20030008822 Use of IL-18 inhibitors for the treatment or prevention of sepsis |
| 01/09/2003 | US20030008818 Compositions containing inclusion complexes |
| 01/09/2003 | US20030008813 Intracellular protein delivery compositions and methods of use |
| 01/09/2003 | US20030008810 Nutritional intervention composition for enhancing and extending satiety |
| 01/09/2003 | US20030008396 Poly(vinyl alcohol) hydrogel |
| 01/09/2003 | US20030008355 Nucleotide sequences coding monclonal antibodyfor use as a tool in genetic engineering |
| 01/09/2003 | US20030008300 Amplification of nitroso compouds in erythrocytes; obtain mammal, inject with therapeutic agent, monitor concentration levels of preferential nitroso compounds |
| 01/09/2003 | US20030008022 Medical effect of jojoba oil |
| 01/09/2003 | US20030008019 Aqueous solution; efficient penetration |
| 01/09/2003 | US20030008018 Acrochordon alleviation |
| 01/09/2003 | US20030008014 Truncated apolipoprotein B-containing lipoprotein particles for delivery of compounds to tissues or cells |
| 01/09/2003 | US20030008012 Bactericide in solid form |
| 01/09/2003 | US20030008010 Aqueous suspension with good redispersibility |
| 01/09/2003 | US20030008009 pH-titratable polyampholytes for delivering polyions to a cell |
| 01/09/2003 | US20030008008 Fast dissolving orally consumable films |
| 01/09/2003 | US20030008007 Release pharmaceutical construct for gastric retention |